BioSpace News Archive

PAVmed Inc. (Nasdaq: PAVM, PAVMZ ), a diversified commercial-stage medical device company today announced that the Company will host a business update conference call on Tuesday, August 16, 2022, at 4:30 PM EDT.

Albireo Pharma, Inc. today announced participation in the 2022 Wedbush PacGrow Healthcare Conference August 9-10, 2022.

Alumis, a precision immunology company incubated by Foresite Labs that is reimagining the discovery, development and treatment of autoimmune disorders, today announced the appointment of Sapna Srivastava, Ph.D., a biotechnology and financial industry leader, to its board of directors.

MyMD Pharmaceuticals, Inc.® (Nasdaq: MYMD) (“MyMD” or “the Company”), announced today the publication of data in the Journal of Gerontology: Biological Sciences (JGBS) from a pre-clinical study of MYMD-1® demonstrating four-fold greater improvements than rapamycin in delaying aging and extending the life of mice who began treatment at the human equivalent of 60 years of age.

Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL), today announced topline results that neither the primary endpoint of Overall Response Rate (ORR) nor the key secondary endpoint in Progression Free Survival (PFS) achieved statistical significance in the multi-center, international Phase III AGENT Study of arfolitixorin in combination with 5-FU, oxaliplatin and bevacizumab in metastatic colorectal cancer (mCRC).

According to Vision Research Report, the global neuromodulation devices market size was estimated at around USD 3.3 billion in 2021 and it is projected to hit around USD 8.54 billion by 2030, growing at a CAGR of 11.14% from 2022 to 2030.

According to Vision Research Reports, the U.S. in vitro diagnostics market was valued at USD 55.3 billion in 2021 and it is predicted to surpass around USD 36.7 billion by 2030 with a CAGR of -4.45% from 2022 to 2030.

According to Vision Research Reports, the global peptide antibiotics market was estimated at USD 4.4 billion in 2021 and it is expected to surpass around USD 6.86 billion by 2030, poised to grow at a CAGR of 5.06% from 2022 to 2030.

The sterilization of medical devices is a vital process for helping to prevent serious infections.

Altamira Therapeutics (“Altamira” or the “Company”) (NASDAQ:CYTO), today announced that its Founder, Chairman and Chief Executive Officer, Thomas Meyer, participated in a video interview with Proactive Investors to discuss the Company’s corporate strategy and its key advantages, catalysts, and market opportunities as it advances towards becoming an RNA therapeutics pure play.